MET exon 14 skipping alterations (METex14) represent one of the newest discovered driver oncogene alterations for non‐small cell lung cancer (NSCLC), which serve to define a distinct elderly patient population. New challenges in detection and treatment have emerged. In the last 15 years, the successes of tumor molecular profiling and therapeutic stratification in patients with advanced‐stage disease have made NSCLC a poster child in the era of precision medicine. Each of the oncogenic drivers defines a distinct patient population. The selection of treatments based on oncogenic drivers such as EGFR, ALK, and ROS1, among others, has been transformative in terms of the duration and quality of life for patients with NSCLC receiving effective inhibitors. METex14 have emerged as one of the newest additions of driver oncogenes for NSCLC. This commentary evaluates the evidence that established MET exon 14 skipping as an actionable driver oncogene in NSCLC, the unique patient population defined by MET exon 14 skipping alterations, and the clinical challenges to care for this elderly patient population.